grant
The Role and Therapeutic Targeting of GPR56 in Colorectal Cancer
Organization UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTONLocation HOUSTON, UNITED STATESPosted 1 Apr 2025Deadline 31 Mar 2030
NIHUS FederalResearch GrantFY20267-Transmembrane Protein with no EGF-Like N-Terminal Domains1ABC20ABCB1ABCB1 geneADGR1ADGR1 geneAdhesionsAdverse effectsAffectAffinityAnti-Cancer AgentsAntibody AffinityAntibody-drug conjugatesAntineoplastic AgentsAntineoplastic DrugsAntineoplasticsBreast Cell GlutaminaseCRISPR approachCRISPR based approachCRISPR methodCRISPR methodologyCRISPR techniqueCRISPR technologyCRISPR toolsCRISPR-CAS-9CRISPR-based methodCRISPR-based techniqueCRISPR-based technologyCRISPR-based toolCRISPR/CAS approachCRISPR/Cas methodCRISPR/Cas technologyCRISPR/Cas9CRISPR/Cas9 technologyCancer CauseCancer DrugCancer EtiologyCancer PatientCancersCas nuclease technologyCell BodyCell Communication and SignalingCell SignalingCellsCessation of lifeCheckpoint inhibitorClinical Treatment MoabClustered Regularly Interspaced Short Palindromic Repeats approachClustered Regularly Interspaced Short Palindromic Repeats methodClustered Regularly Interspaced Short Palindromic Repeats methodologyClustered Regularly Interspaced Short Palindromic Repeats techniqueClustered Regularly Interspaced Short Palindromic Repeats technologyColorectal CancerCombined Modality TherapyDataDeathDevelopmentDiseaseDisease ProgressionDisease ResistanceDisorderDrug resistanceEC 3.5.1.2EvaluationExhibitsFDA approvedFamilyG Protein-Complex ReceptorG Protein-Coupled Receptor 56G Protein-Coupled Receptor GenesG-Protein-Coupled ReceptorsGA ProteinGP170GPCRGPR56Generalized GrowthGenerationsGenesGlutaminaseGoalsGrowthHG38High-Frequency Microsatellite InstabilityHumanIVIS SpectrumCTIVIS imagingIVIS optical imagingIVIS spectral imagingIVIS spectrumIVIS systemImmune checkpoint inhibitorImmuno-PETImmunoPETImmunocompetentIntegrinsIntegrins Extracellular MatrixIntracellular Communication and SignalingIntratumoral heterogeneityKnock-outKnockoutL glutamine amidohydrolaseLGR5LGR5 geneLeadLigandsLiver GlutaminaseMDR-1MDR1MDR1 ProteinMSI-HMalignant CellMalignant NeoplasmsMalignant TumorMediatingMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMiceMice MammalsModelingModern ManMonitorMonoclonal AntibodiesMultidrug Resistance 1Multidrug Resistance Gene-1Multidrug Resistance Gene-1sMultidrug Resistance ProteinsMultidrug Resistant ProteinsMultimodal TherapyMultimodal TreatmentMurineMusNeoplasm MetastasisNeoplastic Disease Chemotherapeutic AgentsOrganoidsP-GPP-GlycoproteinP-Glycoprotein 1 GenePDX modelPGY-1 ProteinPGY1Pathway interactionsPatient derived xenograftPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPb elementPhage DisplayPhenotypePlayPrevention therapyPrognosisRNA SeqRNA sequencingRNAseqRelapseResistanceRoleSafetySecondary NeoplasmSecondary TumorSignal TransductionSignal Transduction SystemsSignalingSiteTM7XN1TestingTherapeuticTissue GrowthToxic effectToxicitiesTreatment FailureTumor CellTumor PromotionTumor-Specific Treatment AgentsUpregulationXenograft Modeladvanced diseaseadvanced illnessanti-cancer drugantigen antibody affinitybiological signal transductioncancer cellcancer metastasiscancer progenitorcancer progenitor cellscancer progressioncancer stem cellcancer stem like cellcandidate selectionchemotherapycolon cancer cell linecolorectal cancer cell linecolorectal cancer therapycolorectal cancer treatmentcombination therapycombined modality treatmentcombined treatmentcross reactivitycytotoxicity testdevelopmentaldrug resistanteffective therapyeffective treatmentheavy metal Pbheavy metal leadheterogeneity in tumorsimmune check point inhibitorimmune competentimmune-PETimprovedin vivo imaging systeminnovateinnovationinnovativeintra-tumoral heterogeneityintratumor heterogeneityknock-downknockdownmAbsmalignancymalignant progenitormalignant stem cellmembermicrobialmonoclonal Absmouse modelmulti-modal therapymulti-modal treatmentmurine modelneoplasm progressionneoplasm/cancerneoplastic cellneoplastic progressionnew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic targetnew therapeuticsnew therapynew therapy targetnext generation therapeuticsnon-invasive imagingnoninvasive imagingnovelnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetoncogenic progenitoroncogenic stem cellsontogenyoverexpressoverexpressionpathwaypatient derived xenograft modelpatient oriented outcomespre-clinical developmentpreclinical developmentpreventpreventingprogenitor like cancer cellprotein protein interactionresistance to Drugresistance to diseaseresistance to therapyresistantresistant diseaseresistant to Drugresistant to diseaseresistant to therapyresponseself-renewself-renewalside effectsocial rolestem like cancer celltargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic resistancetherapeutic targettherapy failuretherapy resistanttranscriptome sequencingtranscriptomic sequencingtreatment resistancetumortumor cell metastasistumor growthtumor heterogeneitytumor progressiontumor xenograftxenograft transplant modelxenotransplant model
Description preview
ABSTRACT:
Colorectal Cancer (CRC) remains the second leading cause of cancer-related deaths as current treatments for
advanced disease have been limited by low response rates and adverse side-effects. Failure of treatment is
attributed to tumor heterogeneity and the presence of cancer stem-like cells (CSCs). Plasticity of CSCs has been
shown to…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click